Crescent Biopharma Inc(CBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CBIO Crescent Biopharma Inc

休市中 12-12 16:00:00 EST

14.09

-1.22

-7.97%

盘后14.09

+0.000.00%

19:31 EST

最高15.58	最低14.00	成交量10.40万
今开15.42	昨收15.31	日振幅10.29%
总市值1.96亿	流通市值6,498万	总股本1,389万
成交额153.55万	换手率2.25%	流通股本461.21万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CBIO","market":"US","secType":"STK","nameCN":"Crescent Biopharma Inc","latestPrice":14.09,"timestamp":1765573200000,"preClose":15.31,"halted":0,"volume":103980,"hourTrading":{"tag":"盘后","latestPrice":14.09,"preClose":14.09,"latestTime":"19:31 EST","volume":468,"amount":6576.1004,"timestamp":1765585897151},"delay":0,"floatShares":4612100,"shares":13892516,"eps":-13.454129,"marketStatus":"休市中","change":-1.22,"latestTime":"12-12 16:00:00 EST","open":15.42,"high":15.575,"low":14,"amount":1535474.53164,"amplitude":0.102874,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-13.454129,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1389330000000,"exchange":"NASDAQ","adjPreClose":15.31,"preHourTrading":{"tag":"盘前","latestPrice":15.136,"preClose":15.31,"latestTime":"07:38 EST","volume":1,"amount":15.136,"timestamp":1765543116659},"postHourTrading":{"tag":"盘后","latestPrice":14.09,"preClose":14.09,"latestTime":"19:31 EST","volume":468,"amount":6576.1004,"timestamp":1765585897151},"volumeRatio":0.5112270332027853,"impliedVol":2.2495,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/CBIO","defaultTab":"news","newsList":[{"id":"1137740447","title":"Crescent Biopharma 宣布与 Kelun-Biotech 达成重大合作，并进行 1.85 亿美元私人配售，推动和扩展全球下一代实体肿瘤治疗药物的管道","url":"https://stock-news.laohu8.com/highlight/detail?id=1137740447","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137740447?lang=zh_cn&edition=full","pubTime":"2025-12-04 19:36","pubTimestamp":1764848174,"startTime":"0","endTime":"0","summary":"Crescent Biopharma 宣布与 Kelun-Biotech 达成重大合作，并进行 1.85 亿美元私人配售，推动和扩展全球下一代实体肿瘤治疗药物的管道。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBIO","BK4139"],"gpt_icon":0},{"id":"1115537632","title":"Crescent Biopharma Inc - 将获得2000万美元的预付款，以及来自科伦博泰生物的最高3000万美元的额外里程碑款项","url":"https://stock-news.laohu8.com/highlight/detail?id=1115537632","media":"美股速递","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115537632?lang=zh_cn&edition=full","pubTime":"2025-12-04 19:32","pubTimestamp":1764847944,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc - 将获得2000万美元的预付款，以及来自科伦博泰生物的最高3000万美元的额外里程碑款项","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1979443071.USD","BK1161","LU1064131003.USD","BK0239","LU2148510915.USD","LU0196878994.USD","06990","BK4139","LU1064130708.USD","CBIO","BK0060","002422","LU1934453819.USD"],"gpt_icon":0},{"id":"1126942018","title":"Crescent Biopharma Inc - 科伦博泰生物-B将获得8000万美元的预付款，以及来自Crescent的最高达12.5亿美元的额外里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1126942018","media":"美股速递","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126942018?lang=zh_cn&edition=full","pubTime":"2025-12-04 19:32","pubTimestamp":1764847941,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc - 科伦博泰生物-B将获得8000万美元的预付款，以及来自Crescent的最高达12.5亿美元的额外里程碑付款","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBIO","LU1064130708.USD","LU1934453819.USD","06990","BK0060","BK1161","LU1979443071.USD","BK4139","BK0239","LU0196878994.USD","LU1064131003.USD","002422","LU2148510915.USD"],"gpt_icon":0},{"id":"1115079280","title":"科伦药业与Crescent Biopharma达成战略合作，共同开发及商业化新型抗肿瘤疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1115079280","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115079280?lang=zh_cn&edition=full","pubTime":"2025-12-04 19:30","pubTimestamp":1764847815,"startTime":"0","endTime":"0","summary":"科伦药业与Crescent Biopharma达成战略合作，共同开发及商业化新型抗肿瘤疗法","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","LU1934453819.USD","BK0060","CBIO","06990","LU1064130708.USD","LU2148510915.USD","002422","LU1064131003.USD","LU1979443071.USD","BK4139","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"1118946436","title":"Crescent Biopharma：截至9月30日现金为1.333亿美元，预计可支持运营至2027年","url":"https://stock-news.laohu8.com/highlight/detail?id=1118946436","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118946436?lang=zh_cn&edition=full","pubTime":"2025-11-06 20:37","pubTimestamp":1762432661,"startTime":"0","endTime":"0","summary":"Crescent Biopharma：截至9月30日现金为1.333亿美元，预计可支持运营至2027年","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBIO","BK4139"],"gpt_icon":0},{"id":"2571337076","title":"凯赛生物拟推2025年员工持股计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2571337076","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571337076?lang=zh_cn&edition=full","pubTime":"2025-09-29 22:11","pubTimestamp":1759155072,"startTime":"0","endTime":"0","summary":"员工持股计划初始设立时持有人总人数不超过155人，其中董事、高级管理人员共6人，具体参加人数根据员工实际缴款情况确定。员工持股计划拟持有的标的股票数量不超过130.00万股，约占员工持股计划草案公布时公司股本总额的0.18%。为满足公司可持续发展的需要及不断吸引和留住优秀人才，员工持股计划拟预留15.00万股作为预留份额，占员工持股计划股票总数的11.54%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929221421a44c8e96&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929221421a44c8e96&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CBIO","BK4139"],"gpt_icon":0},{"id":"2556889051","title":"凯赛生物：累计回购23万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2556889051","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556889051?lang=zh_cn&edition=full","pubTime":"2025-08-01 18:54","pubTimestamp":1754045656,"startTime":"0","endTime":"0","summary":"格隆汇8月1日丨凯赛生物(688065.SH)公布，2025年7月31日，公司通过上海证券交易所交易系统以集中竞价交易方式回购公司股份230,366股,占公司总股本721,289,794股的比例为0.0319%。回购成交的最高价为53.40元/股，最低价为44.08元/股，支付的资金总额为人民币10,497,716.71元（不含印花税、交易佣金等交易费用)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801185648a46f9b1b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801185648a46f9b1b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CBIO"],"gpt_icon":0},{"id":"2550966326","title":"凯赛生物获得发明专利授权：“重组核酸序列、重组表达载体以及基因工程菌”","url":"https://stock-news.laohu8.com/highlight/detail?id=2550966326","media":"证券之星企业动态","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550966326?lang=zh_cn&edition=full","pubTime":"2025-07-12 02:42","pubTimestamp":1752259353,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示凯赛生物新获得一项发明专利授权，专利名为“重组核酸序列、重组表达载体以及基因工程菌”，专利申请号为CN202111155453.8，授权日为2025年7月11日。其中，所述重组核酸序列包括串联启动子、赖氨酸脱羧酶基因以及增强细胞耐受压力的基因，所述串联启动子包括piclR启动子和稳定期特异性启动子。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712025655953f1c89&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712025655953f1c89&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CBIO"],"gpt_icon":0},{"id":"2548692278","title":"凯赛生物：已回购23.04万股公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2548692278","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548692278?lang=zh_cn&edition=full","pubTime":"2025-07-02 16:14","pubTimestamp":1751444051,"startTime":"0","endTime":"0","summary":"格隆汇7月2日丨凯赛生物(688065.SH)公布，2025年6月30日，公司通过上海证券交易所交易系统以集中竞价交易方式回购公司股份230,366股,占公司总股本的比例为0.0319%。回购成交的最高价为53.40元/股，最低价为44.08元/股，支付的资金总额为人民币10,497,716.71元（不含印花税、交易佣金等交易费用)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702161721a72a218e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702161721a72a218e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CBIO","BK4139"],"gpt_icon":0},{"id":"2546624105","title":"Crescent Biopharma(CBIO.US)获Stifel首次覆盖，给予买入评级, 目标价28.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2546624105","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546624105?lang=zh_cn&edition=full","pubTime":"2025-06-25 23:07","pubTimestamp":1750864049,"startTime":"0","endTime":"0","summary":"Crescent Biopharma(CBIO.US)获Stifel首次覆盖，给予买入评级, 目标价28.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/06/25230751310017.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["CBIO"],"gpt_icon":0},{"id":"2545445885","title":"AMAC化纤指数上涨0.75%，前十大权重包含凯赛生物等","url":"https://stock-news.laohu8.com/highlight/detail?id=2545445885","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545445885?lang=zh_cn&edition=full","pubTime":"2025-06-23 22:47","pubTimestamp":1750690041,"startTime":"0","endTime":"0","summary":"金融界6月23日消息，上证指数低开高走，AMAC化纤指数 上涨0.75%，报3461.89点，成交额23.32亿元。数据统计显示，AMAC化纤指数近一个月下跌5.73%，近三个月下跌8.22%，年至今下跌2.18%。从AMAC化纤指数持仓的市场板块来看，深圳证券交易所占比61.42%、上海证券交易所占比38.58%。从AMAC化纤指数持仓样本的行业来看，原材料占比100.00%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623225414978b6a3b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623225414978b6a3b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CBIO","BK4139"],"gpt_icon":0},{"id":"2544723359","title":"Crescent Biopharma获LifeSci Capital首次覆盖，给予优于大市评级, 目标价22.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2544723359","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544723359?lang=zh_cn&edition=full","pubTime":"2025-06-18 19:51","pubTimestamp":1750247499,"startTime":"0","endTime":"0","summary":"Crescent Biopharma(CBIO.US)获LifeSci Capital首次覆盖，给予优于大市评级, 目标价22.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506181956459521c546&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506181956459521c546&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CBIO"],"gpt_icon":0},{"id":"2543633856","title":"Glycomimetics, Inc.盘中异动 早盘大幅跳水5.66%报0.157美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2543633856","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543633856?lang=zh_cn&edition=full","pubTime":"2025-06-13 21:51","pubTimestamp":1749822718,"startTime":"0","endTime":"0","summary":"北京时间2025年06月13日21时51分，Glycomimetics, Inc.股票出现异动，股价急速跳水5.66%。截至发稿，该股报0.157美元/股，成交量44.3583万股，换手率0.69%，振幅6.63%。Glycomimetics, Inc.股票所在的生物技术行业中，整体跌幅为0.68%。其相关个股中，Psyence Biomedical Ltd C/Wts 25/01/2029、Cingulate Inc C/Wts 10/12/2026 、Carisma Therapeutics, Inc.涨幅较大，Nucana Plc、Alzamend Neuro, Inc.、Eyenovia, Inc.较为活跃，换手率分别为446.07%、57.14%、18.98%，振幅较大的相关个股有Klotho Neurosciences Inc C/Wts 21/06/2029 、Carisma Therapeutics, Inc.、Eyenovia, Inc.，振幅分别为35.79%、22.97%、22.85%。Glycomimetics, Inc.公司简介：GlycoMimetics Inc是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250613215158951b2ab3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250613215158951b2ab3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GLYC","CBIO","BK4139"],"gpt_icon":0},{"id":"2542051038","title":"Glycomimetics, Inc.盘中异动 股价大跌5.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2542051038","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542051038?lang=zh_cn&edition=full","pubTime":"2025-06-12 21:36","pubTimestamp":1749735366,"startTime":"0","endTime":"0","summary":"北京时间2025年06月12日21时36分，Glycomimetics, Inc.股票出现异动，股价大幅下跌5.96%。截至发稿，该股报0.156美元/股，成交量23.7348万股，换手率0.37%，振幅4.70%。Glycomimetics, Inc.股票所在的生物技术行业中，整体涨幅为0.40%。其相关个股中，Klotho Neurosciences Inc C/Wts 21/06/2029 、Curevac N.V.、Klotho Neurosciences, Inc.涨幅较大，Nucana Plc、Klotho Neurosciences, Inc.、Polyrizon Ltd.较为活跃，换手率分别为1134.41%、75.40%、46.43%，振幅较大的相关个股有Klotho Neurosciences Inc C/Wts 21/06/2029 、Tnf Pharmaceuticals, Inc.、Immunoprecise Antibodies Ltd.，振幅分别为28.10%、18.69%、16.14%。Glycomimetics, Inc.公司简介：GlycoMimetics Inc是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025061221360695198c01&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025061221360695198c01&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CBIO","GLYC","BK4139"],"gpt_icon":0},{"id":"2379512739","title":"凯赛生物：截至10月31日已回购54.9236万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2379512739","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2379512739?lang=zh_cn&edition=full","pubTime":"2023-10-31 18:12","pubTimestamp":1698747120,"startTime":"0","endTime":"0","summary":"证券日报网讯 10月31日晚间，凯赛生物发布公告称，截至2023年10月31日，公司通过上海证券交易所交易系统以集中竞价交易方式回购公司股份54.9236万股，占公司总股本58337.8039万股的比例为0.0941%。回购成交的最高价为57.37元/股，最低价为52.90元/股，支付的资金总额人民币3057.0741万元（不含印花税、交易佣金等交易费用）。（编辑 何帆）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023103118311783989b56&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023103118311783989b56&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0208","CBIO","688065","GYRE"],"gpt_icon":0},{"id":"2379198955","title":"凯赛生物：累计回购约55万股 占比0.0941%","url":"https://stock-news.laohu8.com/highlight/detail?id=2379198955","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2379198955?lang=zh_cn&edition=full","pubTime":"2023-10-31 17:37","pubTimestamp":1698745056,"startTime":"0","endTime":"0","summary":"凯赛生物（SH 688065，收盘价：53.11元）10月31日晚间发布公告称，截至2023年10月31日，公司通过上海证券交易所交易系统以集中竞价交易方式回购公司股份约55万股，占公司总股本约5.83亿股的比例为0.0941%。2022年1至12月份，凯赛生物的营业收入构成为：合成生物材料行业占比95.55%。凯赛生物的董事长、总裁均是XIUCAI LIU(刘修才)，男，66岁，学历背景为博士。截至发稿，凯赛生物市值为310亿元。文章来源：每日经济新闻原标题：凯赛生物：累计回购约55万股，占比0.0941%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023103117393083d61d06&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023103117393083d61d06&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0208","GYRE","CBIO","688065"],"gpt_icon":0},{"id":"2379589096","title":"Catalyst Biosciences Inc盘中异动 大幅上涨7.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2379589096","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2379589096?lang=zh_cn&edition=full","pubTime":"2023-10-30 21:30","pubTimestamp":1698672625,"startTime":"0","endTime":"0","summary":"北京时间2023年10月30日21时30分，Catalyst Biosciences Inc股票出现波动，股价急速拉升7.88%。Catalyst Biosciences Inc股票所在的生物技术行业中，整体涨幅为0.00%。Catalyst Biosciences Inc公司简介：凯赛生物公司是一家临床阶段生物制药公司。消息层面，截至21时30分，《凯赛生物2023年前三季度净利3.14亿 同比减少35.44%》资讯为影响Catalyst Biosciences Inc的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202310302130258475f4fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202310302130258475f4fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GYRE","CBIO"],"gpt_icon":0},{"id":"2379304977","title":"凯赛生物2023年前三季度净利3.14亿 同比减少35.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2379304977","media":"挖贝网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2379304977?lang=zh_cn&edition=full","pubTime":"2023-10-30 19:01","pubTimestamp":1698663690,"startTime":"0","endTime":"0","summary":"挖贝网2023年10月30日，凯赛生物 近日发布2023年前三季度报,报告期内，公司实现营业收入1,565,490,018.66元,同比减少14.81%；归属于上市公司股东的净利润313,885,180.71元，同比减少35.44%。报告期内研发费用126,413,295.65元，上年同期134,754,753.10元，同比减少6.19%。挖贝网资料显示，凯赛生物的主要业务为新型生物基材料的研发、生产及销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023103019034483d2d8f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023103019034483d2d8f8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CBIO","688065","BK4139","GYRE"],"gpt_icon":0},{"id":"2379307906","title":"凯赛生物：2023年前三季度净利润约3.14亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2379307906","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2379307906?lang=zh_cn&edition=full","pubTime":"2023-10-30 18:57","pubTimestamp":1698663430,"startTime":"0","endTime":"0","summary":"凯赛生物（SH 688065，收盘价：53.78元）10月30日晚间发布三季度业绩公告称，2023年前三季度营收约15.65亿元，同比减少14.81%；归属于上市公司股东的净利润约3.14亿元，同比减少35.44%。2022年1至12月份，凯赛生物的营业收入构成为：合成生物材料行业占比95.55%。凯赛生物的董事长、总裁均是XIUCAI LIU(刘修才)，男，66岁，学历背景为博士。截至发稿，凯赛生物市值为314亿元。文章来源：每日经济新闻原标题：凯赛生物：2023年前三季度净利润约3.14亿元","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023103019100783d2dce7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023103019100783d2dce7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688065","GYRE","CBIO"],"gpt_icon":0},{"id":"2378870508","title":"Catalyst Biosciences Inc盘中异动 早盘急速拉升6.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2378870508","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2378870508?lang=zh_cn&edition=full","pubTime":"2023-10-27 21:43","pubTimestamp":1698414201,"startTime":"0","endTime":"0","summary":"北京时间2023年10月27日21时43分，Catalyst Biosciences Inc股票出现异动，股价大幅拉升6.66%。Catalyst Biosciences Inc股票所在的生物技术行业中，整体跌幅为0.74%。Catalyst Biosciences Inc公司简介：凯赛生物公司是一家临床阶段生物制药公司。消息层面，截至21时43分，《年报季·龙头系列 | 凯赛生物：业绩以及经营效率下滑，估值较低》资讯为影响Catalyst Biosciences Inc的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102721432383978a74&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102721432383978a74&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CBIO","GYRE"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.glycomimetics.com","stockEarnings":[{"period":"1week","weight":0.078},{"period":"1month","weight":0.0797},{"period":"3month","weight":0.1281},{"period":"6month","weight":-0.1025},{"period":"1year","weight":-0.4289},{"period":"ytd","weight":-0.4341}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Crescent Biopharma, Inc.是一家开曼群岛公司，于2003年在特拉华州注册成立，是一家后期临床生物技术公司，致力于通过抑制细胞表面发生的碳水化合物相互作用来改善癌症和炎症性疾病患者的生活。该公司正在开发一种专有的糖模拟物管道，糖模拟物是模仿碳水化合物结构的小分子，参与抑制碳水化合物疾病相关功能的重要生物过程。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":0.019108},{"month":2,"riseRate":0.583333,"avgChangeRate":-0.015525},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.053963},{"month":4,"riseRate":0.416667,"avgChangeRate":-0.063712},{"month":5,"riseRate":0.5,"avgChangeRate":0.092337},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.022838},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.058163},{"month":8,"riseRate":0.416667,"avgChangeRate":-0.053488},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.058271},{"month":10,"riseRate":0.5,"avgChangeRate":0.107936},{"month":11,"riseRate":0.75,"avgChangeRate":0.290074},{"month":12,"riseRate":0.25,"avgChangeRate":-0.017868}],"exchange":"NASDAQ","name":"Crescent Biopharma Inc","nameEN":"Crescent Biopharma Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Crescent Biopharma Inc(CBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Crescent Biopharma Inc(CBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Crescent Biopharma Inc,CBIO,Crescent Biopharma Inc股票,Crescent Biopharma Inc股票老虎,Crescent Biopharma Inc股票老虎国际,Crescent Biopharma Inc行情,Crescent Biopharma Inc股票行情,Crescent Biopharma Inc股价,Crescent Biopharma Inc股市,Crescent Biopharma Inc股票价格,Crescent Biopharma Inc股票交易,Crescent Biopharma Inc股票购买,Crescent Biopharma Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Crescent Biopharma Inc(CBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Crescent Biopharma Inc(CBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}